

March 2021

Curriculum Vitae of Robert Kneller (J.D., M.P.H., M.D.)

email: bobkneller@gmail.com

telephone: 81-80-5526-1264 (Japan cell) or 650-924-9337 (Skype #)

Professional Qualifications

- Licensed to practice **medicine** in Maryland since 15 Oct. 1985. License # D0032919, expires 30 Sept. 2022
- Board Certified in **preventive medicine** since 16 Jan. 1985. Certificate # 51156. Does not expire.
- Licensed to practice **law** in
Massachusetts since 6 Feb 1981, attorney registration # 275840
New York since 22 Dec 1981, registration # 1789536
Minnesota since Sept 1981, registration # 128788.

National Provider Identification Number (for US Medicare & Medicaid):
1063815496

BLS recertified 6 October 2020

ACLS certified 1 November 2020

Career Highlights

- Chief Medical Officer in a Japanese startup developing an innovative enhancer for cancer radiation therapy; responsible for clinical trial planning, global medical needs assessment, and safety/efficacy assessments of comparable therapies.
- Professor in the University of Tokyo, where I.
 - compared US and Japanese vaccine adverse event rates and reporting systems and suggested improvements
 - showed the disproportionate contribution of new companies to the discovery of innovative drugs through an analysis of the research advances and clinical benefits behind all new drugs approved by FDA 1998-2007
 - worked closely with startups to develop promising biomedical therapies
 - improved university-industry technology transfer and entrepreneurship

- Epidemiologist in the National Cancer Institute, NIH, where I
 - co-lead US-China studies on risk factors and preventive measures for gastric cancer
 - lead other research into causes of gastric cancer and cancer risks associated with multiple sclerosis
 - investigated cancer risks associated with occupational benzene exposure
 - negotiated clinical trial collaboration agreements with industry to bring NIH discoveries rapidly to patients
 - negotiated agreements with source countries to develop drugs from natural products.
- Refugee medical work in Turkey, where I provided emergency and primary care for refugees fleeing from Iraq in winter/spring 1991 and documented their mortality experience.

Expertise

- **Medicine**
Board certified in Preventive Medicine. Training and experience in **general medicine, pediatrics, disaster medicine and public health.**
- **Epidemiology**
Medical epidemiology and related statistical analysis developed in a variety of contexts (see Work Experience), including planning, field data collection and publishing results on
 - risk factors for and prevention of stomach and other cancers,
 - infectious disease mortality rates and trends,
 - clinical trial design, and
 - safety and efficacy of drugs and vaccines.
- **Development of pharmaceuticals, vaccines, and medical devices by startups**
Worked with Japanese startups and academic scientists in a variety of therapeutic areas on development strategies, health impacts, clinical trial design, and intellectual property. Co-founded two startups. (See Entrepreneurship)
- **Law**
Expertise in intellectual property, technology license contracts, and collaborative research agreements. Drafted and negotiated agreements on behalf of NIH and Japanese startups. Drafted a patent on which I am an inventor.

Current Residence

4-12-10 Shimomeguro
Meguro-ku, Tokyo 153-0064

Japan

Education

- Swarthmore College, Swarthmore, Pennsylvania USA
B.A. (major physics, minor economics),
- Harvard Law School, Cambridge, Massachusetts, USA
J.D.
- Mayo Medical School, Rochester, Minnesota, USA
M.D.
- Kapiolani Women's and Children's Hospital, Honolulu, Hawaii, USA
pediatric internship
- Johns Hopkins University, Baltimore, Maryland, USA
M.P.H.
- Johns Hopkins University, Baltimore, Maryland, USA
Preventive Medicine Residency
(3-year residency, not including the pediatric PL-1 year)
Residency Director: Andrew Dannenberg, M.D. adannen@uw.edu

Employment

2019 (April) – 2020 (March):

Chief Medical Officer. KORTUC, Inc., Tokyo, Japan.

*Continuing to present as **Scientific Advisor.***

KORTUC is a Japanese startup developing an innovative enhancer to make radiation therapy more effective for cancer patients. Before its incorporation in 2015, I have worked with KORTUC. Accomplishments and duties include:

- Assessing patient series and clinical trial data on efficacy and safety of anti-cancer therapies.
- Clinical trial design.
- Developing a regulatory approval strategy.
- Working with collaborating oncologists in the UK's Institute for Cancer Research to develop the Phase 2 protocol and prepare for the trial in locally advanced breast cancer patients <https://www.clinicaltrials.gov/ct2/show/NCT03946202>.
- Identifying American and Japanese collaborators for clinical trials involving patients with other solid tumors.

Supervisor: Mr. Kazuyuki Matsuda, CEO: kazu.matsuda@kortuc.com

1998 – 2019:

Professor. Research Center for Advanced Science and Technology (RCAST), University of Tokyo, Tokyo, Japan

The University of Tokyo is one of Japan's leading universities. While on the faculty I focused initially on the ecosystem of public-private cooperation and technology transfer and its effect on development of new medical technologies. Over time, this focus shifted to startups and the opportunities and challenges they face in Japan to play a similar role as they do in America and other countries. I co-founded two startups and worked closely with others.

Major research accomplishments include:

- comparisons of Japan's system of public-private cooperation and biomedical innovation with that in the US, including the roles of intellectual property and university translational research,
- an analysis the origins of all new drugs approved by FDA 1998-2007 showing that startups contribute disproportionately to the discovery and early development of innovative, high-benefit drugs
<https://www.nature.com/articles/nrd3251/boxes/bx1>,
- (still ongoing) a comparison of the vaccine adverse (AE) event reporting systems in Japan and the US showing how non-objective factors often influence reported AE rates.

Other key publications listed below, and available at www.robertkneller.com

Supervised two successful doctoral candidates.

RCAST Director: Prof. Ryohei Kanzaki: kanzaki@rcast.u-tokyo.ac.jp

2010 – 2011:

Visiting Professor. Stanford Medical School, Stanford, California

One-year sabbatical to:

- Gain familiarity with new medical procedures & technologies.
- Gain familiarity with how Stanford and UCSF stimulate high impact biomedical discoveries and how these are developed and brought to patients.
- Build bridges between the Bay Area and Japanese biomedical ecosystems.

Host and supervisor: Terrence Blaschke, M.D. blaschke@stanford.edu

1995 -1997:

Medical Officer for clinical development, Technology Transfer Center (TCC), National Cancer Institute (NCI), NIH, Rockville, Maryland

NCI TCC works with private companies and the FDA to ensure that cancer therapies discovered by NIH are rapidly developed to benefit patients.

- I was responsible for agreements with industry to jointly conduct clinical trials to demonstrate the safety and efficacy of new cancer therapies. I also assisted in the design of protocols for these trials.

- I negotiated agreements with source countries to develop drugs derived from natural products.
- I also assessed preclinical safety and efficacy data on new cancer therapies from NIH and recommended which of these new therapies to patent.

Supervised a staff of five professionals.

Supervisor (retired): Karen Maurey: karenmaurey@gmail.com

current TCC Associate Director and former colleague: Kathleen Carroll, PhD, MBA: carrollk@mail.nih.gov

1992 - 1995:

Medical and Program Officer. Fogarty International Center (FIC), NIH

Bethesda, Maryland

FIC is the international office of NIH.

- I managed government to government collaborative research programs, mainly with countries in the Asia Pacific region, and liaised on scientific and policy matters with other US Government agencies.
- I crafted NIH policies on sharing of benefits from natural product drug development, protection of human and animal research subjects, large-scale industry funding for academic laboratories, and rights of patients and research subjects in genomic material.
- I helped ensure that government-funded basic research would not be adversely impacted by WTO rules.
- I also worked with leading Japanese scientists to expand Japan's Human Frontier Science Program to benefit American biomedical researchers.

Supervised one professional staff member.

Supervisor: Jack C Chow, M.D. jackcchow@aol.com

1991 (Oct) – 1992 (May):

Medical Officer. World Health Organization (WHO), Programme for the Control of Acute Respiratory Infections, Geneva, Switzerland

- Developed protocols to prevent, diagnose and treat pneumonia in children in developing countries, and treatment strategies.
- This work partially fulfilled the practicum requirements of the Johns Hopkins Preventive Medicine Residency..

1991 (March) -1991 (June):

Medical relief physician. American Red Cross Society, serving in Turkey.

I was seconded to the International Federation of Red Cross and Red Crescent Societies (IFRC, Geneva) and was the sole physician in an international IFRC field clinic in Ishikveren, one of the largest camps along the Iraq border in the crisis months

following Operation Desert Storm.

- Provided emergency and primary care for Kurdish and other refugees.
- Assessed the overall health status of the camps (sanitation, water, food, security, and access to immunizations).
- Coordinated with other aid organizations.

Later, I treated patients in the Silopi camp and surveyed residents there to quantify and better understand mortality in the first months of the crisis. Published findings available at <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1467-7717.1992.tb00403.x>.

1988 - 1991:

Cancer Epidemiologist. Biostatistics Branch, Division of Cancer Epidemiology & Genetics, NCI, NIH, Rockville, Maryland

Most of my research concerned risk factors for stomach and related GI cancers, work-related hematologic malignancies, and prevention strategies.

- I was lead author on several studies on stomach cancer in American and Chinese populations.
 - One of these was a major US-China collaboration on stomach cancer risk factors which forms the basis of current understanding of stomach cancer development and prevention. I was the NCI operational lead working with the Chinese PI to develop data collection protocols, verify analytical methods, and oversee data collection over several months in Chinese villages.
 - Data included questionnaire-based interviews and biological samples.
 - See <https://academic.oup.com/jnci/article-abstract/84/16/1261/923031>.
- Played a key role in studies on possible links between multiple sclerosis and cancer, and rising incidence of lower esophageal and gastric cardia cancers.
- Planned and obtained data for a US-China collaborative study on risk factors from occupational benzene exposure.
- Publications listed below.

Supervisor: William Blot, PhD william.j.blot@vanderbilt.edu; then Mitchell Gail, MD, PhD gailm@mail.nih.gov

1987 (April – Dec):

Lecturer in Social Medicine. Chinese Academy of Preventive Medicine, Beijing, China

I designed and taught a course on social medicine based my Hopkins MPH course. This course covered:

- the interrelationships between health, behavior, and society
- how epidemiologic analysis can help to understand these relationships.

CAPM was the forerunner of the Chinese Center for Disease Control and Prevention, the equivalent of the U.S. CDC.

- This course in was probably the first to introduce scientists and administrators in this key Chinese medical institute to Western concepts of social medicine.

1986 (August) -1987 (March):

Surgical Resident. Tianjin Children's Hospital, Tianjin, China

I worked as a surgical resident in the main pediatric hospital in one of China's largest cities for eight months, scrubbing in daily and learning how to do surgeries such as hernia repairs and appendectomies. I owe this opportunity to the hospital's Director of Surgery, Dr. Han Mao-tang, whom I came to know in medical school. This was also a unique opportunity to understand medical care and education in China, just as it was opening to the rest of the world.

Foreign Languages

French, Japanese, Mandarin Chinese and Russian

Patents

Co-inventor and author of WO2018102774 (A2) (2018/06/07), Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein A. Priority to US Provisional Application US201662429782P (2016/12/03).

<https://patentscope2.wipo.int/search/en/detail.jsf?docId=WO2018102774>

Awards

- John C Hume award for academic excellence and professional promise to a member of the Johns Hopkins MPH graduating class, May 1986.
- U.S. Public Health Service, National Institutes of Health, Award of Merit, 1994.

Entrepreneurship

Upon request, I will send a list of the startups I have co-founded or advise. The following three are developing therapies with potentially great public health benefit:

- **KORTUC Inc.** <https://kortuc.com/>
(co-founder (2016), board member, and Scientific Advisor; 4 employees)

KORTUC is developing hydrogen peroxide + hyaluronate as a solution injected into tumors just prior to radiation therapy. This raises intra-tumor oxygen and free radical levels, overcoming the radiation resistance seen in many large tumors. Now in Phase 2 trials in the UK, the therapy is low cost, and could be especially beneficial for patients in developing countries or rural areas where tumors are often discovered at late stages when surgery alone is no longer curative.

EXERIENCE SUMMARY:

- Cancer-specific indications for radiotherapy.
 - Stage-specific diagnosis rates of various cancers in various countries.
 - Protocols to stage and treat various cancers.
 - Therapeutic radiation facilities and personnel in various countries.
 - Cancer incidence, prevalence, and other epidemiology.
 - Biologic basis of radiotherapy.
 - Clinical trial design.
 - Recruiting patients for clinical trials.
 - Clinical trial quality control and data integrity.
 - Regulatory approval of drugs and drug-device combination products.
-
- **Hanavax Inc.** <https://www.hanavax.co.jp/en/>
(co-founder (2016) and board member; 3 employees).

I was instrumental in the formation of HanaVax, which is developing a nasal vaccine delivery platform. Its first application uses pneumococcal proteins antigens and protects non-human primates against lethal challenges with *S. pneumoniae*. It produces strong IgA mucosal as well as IgG systemic immunity. We are repositioning this delivery system for SARS-CoV-2 antigens. Success would mean reduction of asymptomatic transmission by enabling recipients to better clear the virus from their nasal and bronchial passages. In helping to build this company, I have gained experience in:

 - Vaccinology.
 - Immunology.
 - Respiratory pathogens and their epidemiology.
 - Health burden of respiratory infections in various countries.
 - Methods for testing vaccine efficacy, including surrogate-for-protection assays.
 - Animal models for diseases.
 - Regulatory approval of vaccines.
 - Vaccine trial design.
 - GLP and GMP standards for drug and vaccine manufacturing.

 - **Sentan Pharma Inc.** <http://www.sentaniryou.co.jp/english/>
(Advisor; 15 employees)

Sentan Pharma's key technology is a unique drug formulation and delivery system suitable for both oral and intramuscular administration. This system holds promise for drugs such as avermectins, frontline therapies against parasitic

infections but whose serum solubility is low. This drug encapsulation system increases the solubility of avermectins and enables smaller doses. I was involved in selecting an appropriate disease to target (we settled on trypanosomiasis) and developing a protocol to show proof of concept in an animal model.

EXPERIENCE SUMMARY:

- Epidemiology of parasitic diseases and their significance for human and animal health.
- Drug absorption, solubility, metabolism, excretion.
- Funding sources for neglected diseases.

Selected Publications

English publications from the University of Tokyo

(complete list with download links at www.robertkneller.com)

Yasuko Inokuma, Robert Kneller. Vaccine adverse event reports in Japan and the United States: Imprecision in medical judgements and implications for vaccination programs in the Covid era. (under journal review)

Amir Farmanbar, Robert Kneller, Sanaz Firouzi. RNA sequencing identifies clonal structure of T-cell repertoires in patients with adult T-cell leukemia/lymphoma. *NPJ Genomic Medicine* (2019) 4(10)(May). PMID: 31069115 PMCID: PMC6502857 DOI: 10.1038/s41525-019-0084-9 <https://www.nature.com/articles/s41525-019-0084-9>

Sanaz Firouzi, Amir Farmanbar, Wojciech Makałowski, Robert Kneller, Masako Iwanaga, Atae Utsunomia, Kenta Nakai, Toshiki Watanabe. 2018. Mutational intratumor heterogeneity is a complex and early event in the development of adult T-cell leukemia/lymphoma. *Neoplasia* 20 (9)(Sept): 883-893. PMID: 30032036 PMCID: PMC6074008 DOI: 10.1016/j.neo.2018.07.001

Robert Kneller, Marcel Mongeon, Jeff Cope, Cathy Garner, Philip Ternouth. 2014. Industry-university collaborations in Canada, Japan, the UK and USA – with emphasis on publication freedom and managing the intellectual property lock-up problem. *PLOS ONE* 9 (3) (Mar)(e90302). PMID: 24632805 PMCID: DOI: 10.1371/journal.pone.0090302

Kneller, Robert. 2010. Importance of new companies for drug discovery: origins of a decade of new drugs. *Nature Reviews Drug Discovery* 9 (11)(Nov):867-882. PMID: 21031002 DOI: 10.1038/nrd3251.

Kneller, RW. 2007. *Bridging Islands: Venture Companies and the Future of Japanese and American Industry*. Oxford U. Press. ISBN-13: 978-0199268801. ISBN-10:

0199268800

Kneller, RW. 2005. Correspondence: The national origins of new drugs. *Nature Biotechnology* 23(6) (June), pp. 655-656. PMID: 15940228 DOI: 10.1038/nbt0605-655

Kneller, RW. 2003. Autarkic drug discovery in Japanese pharmaceutical companies: insights into national differences in industrial innovation. *Research Policy* 32(10)(Dec): 1805-1827. DOI: S0048-7333(03)00062-3

Kneller, RW. 2003. University-industry cooperation and technology transfer in Japan compared with the US: another reason for Japan's economic malaise? *University of Pennsylvania Journal of International Economic Law* Vol. 24(2) pp 329-449 (summer). <https://heinonline.org/HOL/Page?collection=journals&handle=hein.journals/upjiel24&id=341>

Kneller, RW. 2001 'Espionage' charge may be based on a misunderstanding of the rules (letter). *Nature* 411(6841): (28 June) 991. PMID: 11429568 DOI: 10.1038/35082736

Kneller, RW. 2001. Technology transfer, a review for biomedical researchers. *Clinical Cancer Research* 7(4): 761-778 (April). PMID: 11309320

Kneller RW. 1999. University-Industry Cooperation in Biomedical Research in Japan and the U.S. Chapter 16 in Branscomb LM, Kodama F and Florida RL (eds.), *Industrializing Knowledge: University-Industry Linkages in Japan and the United States*. Cambridge: MIT Press, 1999. pp. 410-438.

Kneller RW. 1999. The Role of Intellectual Property in University-Industry Technology Transfer in Japan. *Science and Public Policy* 26(2):113-124 (April). DOI: [147154399781782545](https://doi.org/10.1093/scipub/26.2.113)

Publication on Refugee Medical Relief Work:

Kneller RW, Ingolfsdottir K, Revel JP: 1992. The mortality experience of Kurdish refugees in Turkey. *Disasters* 16(3):249-54. DOI: j.1467-7717.1992.tb00403.x

Publications from the U.S. National Institutes of Health:

Cragg GM, Boyd MR, Khanna R, Kneller R, Mays TD, Mazan KD, Newman DJ, Sausville EA. 1999. International collaboration in drug discovery and development: the NCI experience. *Pure and Applied Chemistry* 71(9):1819-1833.

Cragg GM, Boyd MR, Christini MA, Kneller R, Mays TD, Mazan KD, Newman DJ, Sausville EA. Screening of natural products of plant, microbial and marine origin: the NCI experience. In Wrigley S, Hayes M, Thomas R, Chrystal E (eds.). *Phytochemical Diversity: A Source of New Industrial Products*. Cambridge, Royal Society of Chemistry (proceedings of a symposium held at the University of Sussex, UK on 15-17 April, 1996), 1997; pp 1-29.

Zhang L, Blot WJ, You WC, Chang YS, Kneller RW, Jin ML, Li JY, Zhao L, Liu WD, Zhang JS, Ma JL, Samloff IM, Correa P, Blaser MJ, Xu GW, Fraumeni JF Jr. Helicobacter Pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. *Cancer Epidemiology, Biomarkers and Prevention* 5(8):627-630, 1996 (Aug). PMID: 8824365

Kneller RW. Risks of Major Cancers: Stomach. In *Cancer Rates and Risks, 4th Ed*. NIH Publication No. 96-691, 1996; 191-93.

You WC, Zhang L, Yang CS, Issaq H, Fox SD, Utermahlen WE, Zhao L, Keefer L, Liu WD, Chow WH, Ma JL, Kneller R, Ho MYK, Fraumeni JF Jr., Xu GW, Blot WJ. Nitrite, N-nitroso, and other analytes in physiological fluids in relation to precancerous gastric lesions. *Cancer Epidemiology, Biomarkers and Prevention* 5(1):47-52, 1996 (Jan). PMID: 8770466

You WC, Blot WJ, Chang YS, Zhang L, Zhao L, Liu WD, Li JY, Jin ML, Kneller RW, Xu GW, Fraumeni JF Jr. Epidemiologic studies of precancerous gastric lesions in Shandong Province of China. In Nishi M, Sugano H, Takahashi T (eds.). *1st International Gastric Cancer Congress* (Kyoto, March 29-April 1, 1995). Bologna, Monduzzi Editore, 1995; 373-377.

Yin SN, Linet MS, Hayes RB, Li GL, Dosemeci M, Wang YZ, Chow WH, Jiang ZL, Wacholder S, Zhang WU, Dai TR, Chao XJ, Zhang XC, Ye PZ, Kuo QR, Meng JF, Zhou JS, Lin XF, Ding CY, Kneller RW, Blot WJ. Cohort study among workers exposed to benzene in China: I. General methods and resources. *American Journal of Industrial Medicine*. 1994; 26(3):383-400. PMID: 7977412 DOI: 10.1002/ajim.4700260312

Dosemeci M, Li GL, Hayes RB, Yin SN, Linet M, Chow WH, Wang YZ, Jiang ZL, Dai TR, Zhang WU, Chao XJ, Ye PZ, Kuo QR, Fan YH, Zhang XC, Lin XF, Meng JF, Zhou JS, Wacholder S, Kneller R, Blot WJ. Cohort study among workers exposed to benzene in China: II. Exposure assessment. *American Journal of Industrial Medicine*. 1994 (Sept); 26 (3):401-411. PMID: 7977413 DOI: 10.1002/ajim.4700260313

Zhang L, Blot WJ, You WC, Chang YS, Liu XQ, Kneller RW, Zhao L, Liu WD, Li JY, Jin ML, Xu GW, Fraumeni JF Jr, Yang CS. Serum micronutrients in relation to pre-cancerous gastric lesions. *Int J Cancer* 1994 (Mar); 56 (5):650-654. PMID: 8314341 DOI:

10.1002/ijc.2910560508

Chang Y, You W, Zhang L, Zhao L, Ma J, Liu X, Liu W, Kneller RW, Zhang J, Samloff MI, Blot WJ. Factors influencing serum pepsinogen levels in a Chinese population at high risk of stomach cancer. *Chinese Journal of Cancer Research* 1993; 5:157-64.

You W, Blot WJ, Chang Y, Li J, Jin M, Xie Y, Kneller RK, Yang B, Han Z, Liu W, Zhao L, Zhang L, Yang Z, Fraumeni JF Jr, Xu G. Age and site-specific prevalence rates of precancerous gastric lesions in a high-risk population for stomach cancer. *Chinese Journal of Cancer Research* 1993; 5(2):83-88.

You WC, Blot WJ, Li JY, Jin ML, Chang YS, Kneller RW, Zhang L, Han ZX, Zeng XR, Liu WD, Zhao L, Correa P, Fraumeni JF Jr, Xu GW. Precancerous gastric lesions in a population at high risk for stomach cancer. *Cancer Res* 1993 (Mar); 53(6):1317-1321. PMID: 8443811

You WC, Blot WJ, Zhang L, Kneller RW, Li JY, Jin ML, Chang YS, Zeng XR, Zhao L, Fraumeni JF Jr, Xu GW, Samloff MI. Serum pepsinogens in relation to precancerous gastric lesions in a population at high for gastric cancer. *Cancer Epidemiology, Biomarkers and Prevention* 1993 (Mar); 2(2):113-117. PMID: 8467245

Wei-cheng You, William J. Blot, Yun-sheng Chang, Ji-you Li, Mao-lin Jin, Yong-xing Zhao, Robert W. Kneller, Yu-quan Xie, Lian Zhang, Guang-wei Xu, Joseph F. Fraumeni, Jr. Comparison of the Anatomic Distribution of Stomach Cancer and Precancerous Gastric Lesions. *Jpn J Cancer Res.* 1992 Nov; 83(11): 1150–1153. PMID: 1483930 PMCID: PMC5918719 DOI: 10.1111/j.1349-7006.1992.tb02738.x

Kneller RW, You WC, Chang YS, Liu WD, Zhang L, Zhao L, Xu GW, Fraumeni JF Jr, Blot WJ. Cigarette smoking and other risk factors for the progression of precancerous stomach lesions. *J Natl Cancer Inst* 1992 (Aug); 84 (16):1261-1266. PMID: 1640486 DOI: 10.1093/jnci/84.16.1261

Kneller RW, Guo WD, Hsing AW, Chen JS, Blot WJ, Li JY, Forman D, Fraumeni JF Jr. A correlation study of risk factors for stomach cancer in 65 Chinese counties. *Cancer Epidemiology, Biomarkers and Prevention* 1992 (Jan); 1(2):113-118. PMID: 1306092

Moller H, Kneller RW, Boice JD Jr, Olsen JH. Cancer incidence following hospitalization for multiple sclerosis in Denmark. *Acta Neurologica Scandinavica* 1991(Sept): 84(3):214-220. PMID: 1950464 DOI: 10.1111/j.1600-0404.1991.tb04941.x

Kneller RW, McLaughlin JK, Bjelke E, Schuman LM, Blot WJ, Wacholder S, Gridley G, CoChien HT, Fraumeni JF Jr. A cohort study of stomach cancer in a high-risk American population. *Cancer* 1991 (August); 68 (3):672-678. PMID: 2065291 DOI: 10.1002/1097-0142(19910801)68:3<672::aid-cnrc2820680339>3.0.co;2-t

Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia in the United States. *Journal of the American Medical Association*. 1991 (March); 265(10):1287-1289. PMID: 1995976. doi:10.1001/jama.1991.03460100089030

You WC, Chang YS, Yang ZT, Xu GW, Blot WJ, Kneller RW, Keefer L, Fraumeni JF Jr. Etiologic research on stomach cancer and its precursor lesions in Shandong, China. In O'Neill IK, Chen JS, Lu SH, Bartsch H (eds.). *Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins*. Lyon, International Agency for Research on Cancer, 1991; 33-38. PMID: 1855874

Gao YT, McLaughlin JK, Gao RN, Kneller RW, Liu MH, Sheng JP, Yu MW. Investigation of occupational cancer incidence in urban Shanghai: I. Background and methods. *Tumor (Shanghai)* 1990; 10:49-54.

Kneller RW, Gao YT, McLaughlin JK, Gao RN, Blot WJ, Liu MH, Sheng JP, Fraumeni JF Jr. Occupational risk factors for gastric cancer in Shanghai, China. *American Journal of Industrial Medicine*. 1990 (Jan); 18 (1):69-78. PMID: 2378371 DOI: 10.1002/ajim.4700180108

Publication from Mayo Medical School:

Kottke BA, Zinsmeister AR, Holmes DR, Kneller RW, Hallaway BJ, Mao SJT: Apolipoproteins and coronary artery disease. *Mayo Clinic Proceedings* 61 (5):318-321, 1986. PMID: 3702492 DOI: 10.1016/s0025-6196(12)61947-8

Publication from Harvard Law School:

Kneller RW: Human rights, politics, and the multilateral development banks. *Yale Studies in World Public Order* [now the *Yale Journal of International Law*] 6 (2):361-428, 1980 (spring). <https://digitalcommons.law.yale.edu/yjil/vol6/iss2/5/>